Black Hispanic Patients Less Likely to Get Lifesaving Liver Cancer Treatment Skip to main content Close Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Menu Close Call 1-800-CEDARS-1 toggle search form Close Los Angeles, 07 June 2022 06:07 AM America/Los_Angeles Black Hispanic Patients Less Likely to Get Lifesaving Liver Cancer Treatment A new study from Cedars-Sinai Cancer shows that Black and Hispanic patients are less likely to receive the most effective treatment for liver cancer. Photo by Getty. Cedars-Sinai Study Reveals Significant Racial and Ethnic Disparities in Receiving Immunotherapy for Advanced Liver Cancer Racial and ethnic minorities diagnosed with advanced liver cancer have a lower chance of receiving immunotherapy, the most effective treatment for patients with the disease, according to a new study led by Cedars-Sinai Cancer investigators. The study, published in the peer-reviewed journal Hepatology, found Black and Hispanic patients were significantly less likely to receive immunotherapy compared with white patients, even though the researchers found immunotherapy to be more effective than the traditional treatment of chemotherapy for advanced-stage liver cancer in a wider patient population. In recent years, immunotherapy using immune checkpoint inhibitors has revolutionized the treatment of many cancers, including liver cancer. The immunotherapy combination—atezolizumab-bevacizumab—was approved in 2020 as a first-line therapy for patients with advanced liver cancer. The clinical trial that led to the Food and Drug Administration approval showed that the therapy not only improved the overall survival and reduced the risk of death by 42%, but the percentage of patients whose cancer shrank or disappeared more than doubled. “Although it is very encouraging to see the effectiveness of this promising treatment outside of clinical trials in a broader population, it is very unfortunate to see that Black and Hispanic patients have a lower chance of receiving such an effective treatment for their cancer,” said Ju Dong Yang, MD, medical director of the Liver Cancer Program at Cedars-Sinai Cancer and senior author of the study. Historically, racial and ethnic minorities have been underrepresented in clinical trials and experimental treatments for cancer. As with other therapies, there is also a concern for potential racial-ethnic disparities in early access to immunotherapy among patients with liver cancer in the United States. To investigate the potential disparities and the effectiveness of immunotherapy for advanced liver cancer, Yang and his team used the U.S. National Cancer Database to review medical records and outcome data from 3,990 patients with stage 3 or stage 4 liver cancer. They found 3,248 of the patients were treated with chemotherapy and 742 were treated with immunotherapy. During the study period, however, the annual proportion of patients receiving immunotherapy steadily increased. Key findings from the analysis:The two treatment groups had similar age and sex distributions, with the median age being 65 and a male predominance. When compared with patients treated with chemotherapy, patients with immunotherapy had higher proportions of white (66.6% vs. 61.9%) and Asian (10.3% vs. 7.9%) patients.Hispanic (9.1% vs. 12.4%) and Black (14% vs. 17.8%) patients treated with immunotherapy had lower proportions when compared to patients treated with chemotherapy.A higher proportion of patients who received immunotherapy belonged in the highest income bracket, lived in neighborhoods with high average education levels and were treated at academic medical centers. In addition, the analysis showed that receiving immunotherapy over chemotherapy was associated with improved survival. “Despite the positive results showing the overall efficacy of immunotherapy for patients with advanced liver cancer, this study highlights significant racial, socioeconomic and regional disparities in access to immunotherapy, which could be a surrogate for clinical trial participation and early access to novel experimental therapy,” said Robert A. Figlin, MD, deputy director of Cedars-Sinai Cancer. A comprehensive approach involving all stakeholders will be needed to eliminate disparities in access to clinical trials and novel experimental treatment to make it an available option for patients across all demographics and socioeconomic backgrounds in the United States, noted Yang. “A multilevel, team-based approach designed to eliminate biases and mistrust, and to facilitate effective communications with minority patients, will be critical for future success,” Yang said. Read more on the Cedars-Sinai Blog: Immunotherapy: The Fourth Pillar of Cancer Care Follow Cedars-Sinai Academic Medicine on Twitter for more on the latest basic science and clinical research from Cedars-Sinai. Related Headlines RSS feed - Related Headlines (opens in new window) View all headlines - Related Headlines Cancer Patient Sails Again September 19, 2022 06:00 AM America/Los_Angeles Jeannea Jordan, who turns 80 in October, is a local sailing pioneer who began racing and cruising her 30-foot sailboat 25 years ago when few women were part of the sport. When a tumor on her spine ran her aground last year and her oncologist at … Read more Study Active Surveillance an Effective Option for Thyroid Cancer September 15, 2022 08:01 AM America/Los_Angeles A novel clinical trial from Cedars-Sinai Cancer shows that active surveillance is an effective treatment for many low-risk thyroid cancer patients. The study, published in JAMA Oncology, also showed for the first time that patients who opted for … Read more Study Patients Prefer Stool Test to Colonoscopy September 12, 2022 10:00 AM America/Los_Angeles Three-quarters of people prefer to do a fecal immunochemical test (FIT) rather than a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study.Unlike colonoscopies, FIT doesn’t require lengthy preparation, … Read more Show previous items Show next items Contact the Media Team Email: [email protected] Contact Denise HeadyManager, Science Communications denise.heady@cshs.org 626‐378‐8184 Share this release Black Hispanic Patients Less Likely to Get Lifesaving Liver Cancer Treatment Share on: Twitter Share on: Facebook Share on: LinkedIn Search Our Newsroom Social media Visit our Facebook page (opens in new window) Follow us on Twitter (opens in new window) Visit our Youtube profile (opens in new window) (opens in new window) Latest news 07 Oct 2022 - HealthDay: Black Women Less Likely to Get Laparoscopic Fibroid Surgeries 07 Oct 2022 - Faculty Publications: Sept. 29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Booster? Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics 04 Oct 2022 - Cedars-Sinai Showcases Hispanic and Latinx Art Newsroom Home